Navigation Links
Will Lipodissolve Continue to Remain Popular?
Date:12/12/2007

Leading Dermatologist Doing His Part to Warn Consumers

OMAHA, Neb., Dec. 12 /PRNewswire/ -- Lipodissolve, a treatment for unwanted fat, has been in the news for the past several years with significant controversy about its effectiveness and safety. Now, Fig, the parent company for up to 18 facilities around the country that offer this treatment and defender of this procedure, has closed its stores and is considering declaring bankruptcy. This is in addition to a longtime 'unsatisfactory' rating by the St. Louis Better Business Bureau, with 102 complaints over a year's period.

Despite the closure of this company, there are many companies still selling the non FDA approved substance, PC/DC, which is used for this procedure. Joel Schlessinger, M.D., Board-Certified Dermatologist and Board-Certified General Cosmetic Surgeon and immediate past-president of the American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS), has been involved in spotlighting the dangers of treatment. He is also involved in efforts to stop this treatment from being performed in his state, Nebraska. Just Monday, December 10th, Kansas enacted stricter restrictions on this procedure.

"It doesn't surprise me that Fig closed down -- the handwriting was on the wall when they received the unsatisfactory rating from the BBB. While I've been working on the Lipodissolve issue, many people have sustained harm from this unapproved procedure. Now, countless people have lost their money without any recourse due to the financial uncertainty of this company," says Schlessinger.

"Patient safety shouldn't be put in jeopardy for the sake of making a profit," said Joel Schlessinger M.D., founder of LovelySkin.com. "I've seen half a dozen cases of patients who received treatments and then had pain, swelling, bruising, bloating in the treatment areas, irregular dimpling and divots in the skin. Hopefully, this closure will stop some of this from happening."

Dr. Schlessinger is available for comment on Lipodissolve and its lack of safety. Interviews with Dr. Schlessinger are available and interested media may contact the company at 772-633-8337.

About Dr. Schlessinger

Joel Schlessinger M.D., board-certified dermatologist and general cosmetic surgeon, is the immediate past-president of ASCDAS and the Nebraska Dermatology Society. He continues to work with the FDA and the Nebraska State Board of Healing Arts to regulate Lipodissolve.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Joel Schlessinger, MD http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=35185


'/>"/>
SOURCE Joel Schlessinger M.D.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Lipodissolve - Is it Safe???
2. Battle Continues Over Vietnam PTSD Numbers
3. Continued Statin Use Boosts Post-Stroke Outcomes
4. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
5. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
6. Securians Minnesota Life Continues to Climb Group Life Rankings
7. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
8. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
9. United States continues to have highest level of health spending
10. LehmanMillet Continues Expansion with Strategic Hires
11. Pink Ribbon Bagels Continue the Fight for a Cure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new ... invalid because it does not obey the rules Congress has directed the CBO to ... which the GOP reform would restore. Yet, it estimates a reduction in employer-based coverage ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents ... June 9--24, 2017. This sacred and spiritual journey during the Summer Solstice ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will ... The majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
(Date:3/24/2017)... ... 24, 2017 , ... Empower Brokerage, located in Southlake, Texas, ... programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” program ... to teach how to maximize their sales efforts, as well as how to ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of published ... with his wife, Anna Marie. He and his wife are the proud parents of ... author of “Shadow and Substance.” , “Love, the agape kind, is seen as more ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
(Date:3/24/2017)... India , March 24, 2017 A ... market has been growing rapidly as the global sales of Adcetris ... the growth in the antibody drug conjugates market is driven by ... of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology: